CO6511284A2 - Conjugados peg-lipido puros - Google Patents
Conjugados peg-lipido purosInfo
- Publication number
- CO6511284A2 CO6511284A2 CO11181678A CO11181678A CO6511284A2 CO 6511284 A2 CO6511284 A2 CO 6511284A2 CO 11181678 A CO11181678 A CO 11181678A CO 11181678 A CO11181678 A CO 11181678A CO 6511284 A2 CO6511284 A2 CO 6511284A2
- Authority
- CO
- Colombia
- Prior art keywords
- synthesis
- peg
- conjugates
- lipido
- glycerol
- Prior art date
Links
- 239000002202 Polyethylene glycol Substances 0.000 abstract 5
- 230000015572 biosynthetic process Effects 0.000 abstract 5
- 229920001223 polyethylene glycol Polymers 0.000 abstract 5
- 238000003786 synthesis reaction Methods 0.000 abstract 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 2
- 150000002632 lipids Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 239000007858 starting material Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/77—Polymers containing oxygen of oxiranes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L63/00—Compositions of epoxy resins; Compositions of derivatives of epoxy resins
- C08L63/10—Epoxy resins modified by unsaturated compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21762709P | 2009-06-02 | 2009-06-02 | |
| US28406509P | 2009-12-12 | 2009-12-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6511284A2 true CO6511284A2 (es) | 2012-08-31 |
Family
ID=43298359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11181678A CO6511284A2 (es) | 2009-06-02 | 2011-12-30 | Conjugados peg-lipido puros |
Country Status (15)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9393315B2 (en) | 2011-06-08 | 2016-07-19 | Nitto Denko Corporation | Compounds for targeting drug delivery and enhancing siRNA activity |
| US20120202890A1 (en) * | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| WO2012122144A1 (en) * | 2011-03-07 | 2012-09-13 | Wu Nian | Highly monodisperse branched peg-lipid conjugates |
| US10196637B2 (en) | 2011-06-08 | 2019-02-05 | Nitto Denko Corporation | Retinoid-lipid drug carrier |
| US8883177B2 (en) | 2011-06-28 | 2014-11-11 | Nian Wu | Pharmaceutical compositions for parenteral administration |
| JP6051758B2 (ja) * | 2011-10-17 | 2016-12-27 | 日油株式会社 | ジアシルグリセロールと結合した分岐型ポリエチレングリコール、その製造方法およびポリエチレングリコール修飾リポソーム |
| WO2014031429A2 (en) | 2012-08-21 | 2014-02-27 | Opko Pharmaceuticals, Llc | Liposome formulations |
| US11458199B2 (en) | 2012-08-21 | 2022-10-04 | Opko Pharmaceuticals, Llc | Liposome formulations |
| EP2887923B1 (en) | 2012-08-24 | 2023-04-05 | Sun Pharmaceutical Industries Limited | Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions |
| WO2015021044A1 (en) * | 2013-08-05 | 2015-02-12 | University Of Rochester | Compositions and methods for stimuli-responsive release of a therapeutic agent |
| US10835608B2 (en) * | 2013-12-05 | 2020-11-17 | Nian Wu | Polymer-carbohydrate conjugates for drug delivery technology |
| JP6461973B2 (ja) * | 2013-12-20 | 2019-01-30 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ２以上の疎水性ドメインおよびｐｅｇ部分を含む親水性ドメインを含む化合物の、細胞の安定化のための使用 |
| JP6302560B2 (ja) | 2013-12-20 | 2018-03-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリエチレングリコール部分を含む化合物を用いて支持体に細胞を固定化する方法 |
| WO2015091958A1 (en) * | 2013-12-20 | 2015-06-25 | Roche Diagnostics Gmbh | Compounds comprising one or more hydrophobic domains and a hydrophilic domain comprising peg moieties, useful for binding cells |
| AU2015360794B2 (en) | 2014-12-08 | 2021-07-08 | The Board Of Regents Of The University Of Texas System | Lipocationic polymers and uses thereof |
| US10064954B2 (en) * | 2015-06-23 | 2018-09-04 | Nian Wu | Polymer-cyclodextrin-lipid conjugates |
| JP7041616B2 (ja) | 2015-09-14 | 2022-03-24 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | リポカチオン性デンドリマーおよびその使用 |
| US20190231885A1 (en) | 2015-11-10 | 2019-08-01 | Sun Pharma Global Fze | Topical formulations and uses thereof |
| WO2017099823A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Compositions and methods for delivery of therapeutic agents |
| CN106905120B (zh) * | 2015-12-21 | 2020-04-28 | 北京键凯科技股份有限公司 | Y型多缩乙二醇衍生物及其制备方法 |
| SG11201906729RA (en) | 2016-02-29 | 2019-08-27 | Sun Pharma Global Fze | Topical cyclosporine-containing formulations and uses thereof |
| ES2985317T3 (es) | 2016-05-16 | 2024-11-05 | Univ Texas | Composiciones para la distribución de ARNt en nanopartículas y procedimientos de uso de las mismas |
| EP3458032A4 (en) | 2016-05-16 | 2019-12-25 | The Board of Regents of The University of Texas System | CATIONIC SULFONAMIDE AMINOLIPIDS AND AMPHIPHILE ZWITTERIONIC AMINOLIPIDS |
| JP7216332B2 (ja) * | 2018-03-20 | 2023-02-01 | 日油株式会社 | 分岐型単分散ポリエチレングリコール、中間体およびその製造方法 |
| JP7177392B2 (ja) * | 2018-03-29 | 2022-11-24 | 日油株式会社 | トリチル基含有単分散ポリエチレングリコールの精製方法 |
| WO2019191597A1 (en) * | 2018-03-30 | 2019-10-03 | The Board Of Regents Of The University Of Oklahoma | Very long chain saturated fatty acid compounds, compositions containing same, and methods of use |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| JP7425066B2 (ja) | 2018-09-04 | 2024-01-30 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 核酸を臓器特異的送達するための組成物および方法 |
| EP3846857A4 (en) | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| CN112996854B (zh) | 2018-09-19 | 2024-08-30 | 摩登纳特斯有限公司 | 高纯度peg脂质和其用途 |
| JP6805385B1 (ja) * | 2020-08-31 | 2020-12-23 | ジェイ−ネットワーク，インコーポレイテッド | 表皮内の保湿関連物質の発現増強剤 |
| IL301950B2 (en) | 2020-10-09 | 2025-09-01 | Univ Texas | Pre-stabilized hmpv f proteins |
| JP6860739B1 (ja) * | 2020-11-20 | 2021-04-21 | ジェイ−ネットワーク，インコーポレイテッド | 表皮内の抗酸化物質の発現増強剤 |
| CN114685778B (zh) * | 2020-12-30 | 2023-10-17 | 苏州艾博生物科技有限公司 | 长循环阳离子脂质体的合成方法 |
| EP4288107A4 (en) | 2021-02-08 | 2025-10-15 | Univ Texas | COMPOSITIONS OF UNSATURATED DENDRIMERS, RELATED FORMULATIONS AND METHODS OF USE THEREOF |
| KR20230175196A (ko) | 2021-03-23 | 2023-12-29 | 리코드 테라퓨틱스, 인크. | 폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법 |
| IL307874A (en) | 2021-04-22 | 2023-12-01 | Univ Texas | All-in-one DENDRIMER-based lipid particles enable precise gene editing mediated by HDR IN VIVO |
| US20240350640A1 (en) | 2021-06-30 | 2024-10-24 | Jenkem Technology Co., Ltd. (Tianjin) | Polyethylene glycol lipid and use thereof |
| CN113461929B (zh) * | 2021-07-13 | 2023-04-21 | 浙江倍合德制药有限公司 | 一种tpgs系列产品的精制提纯方法 |
| CN116410460B (zh) * | 2021-12-29 | 2025-08-05 | 辅必成（上海）医药科技有限公司 | 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇2000的制备方法 |
| CN114507342B (zh) * | 2022-03-18 | 2024-03-19 | 江苏东南纳米材料有限公司 | 一种1,2-二肉豆蔻酰-rac-甘油-3-甲氧基聚乙二醇及其中间体的制备方法 |
| EP4504265A1 (en) * | 2022-04-05 | 2025-02-12 | Capstan Therapeutics, Inc. | Peg-lipids and lipid nanoparticles |
| CN114524943B (zh) * | 2022-04-22 | 2022-09-16 | 天津凯莱英制药有限公司 | 聚乙二醇-甘油衍生物及其中间体各自的制备方法 |
| CN117003807A (zh) * | 2022-04-28 | 2023-11-07 | 北京科兴中维生物技术有限公司 | 一种结构脂质化合物及其制备方法和用途 |
| WO2024105071A1 (en) * | 2022-11-15 | 2024-05-23 | Evonik Operations Gmbh | Polyoxyalkylene-1,2-dimyristoyl-glycerol compounds, wherein the polyoxyalkylene is a poly(ethylene oxide) having c1 to c3-alkyloxymethyl side chains |
| CN120693181A (zh) | 2022-12-08 | 2025-09-23 | 瑞科德治疗公司 | 脂质纳米颗粒组合物及其用途 |
| CN120569211A (zh) | 2023-01-09 | 2025-08-29 | 得克萨斯州大学系统董事会 | 融合前稳定的人副流感病毒3f蛋白 |
| CN116178733B (zh) * | 2023-03-03 | 2023-08-01 | 浙江博美生物技术有限公司 | 一种基于三官能团氨基酸的支化单分散peg衍生物、制备方法和应用 |
| US12364773B2 (en) | 2023-12-01 | 2025-07-22 | Recode Therapeutics, Inc. | Lipid nanoparticle compositions and uses thereof |
| WO2025137646A1 (en) | 2023-12-22 | 2025-06-26 | Recode Therapeutics, Inc. | Gene editing methods and compositions for treating cystic fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5827533A (en) * | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| US7141552B2 (en) * | 2000-01-10 | 2006-11-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of lipid conjugates in the treatment of diseases |
| CA2551022C (en) * | 2003-09-15 | 2013-06-04 | Protiva Biotherapeutics, Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| CA2998412C (en) * | 2004-11-12 | 2024-01-02 | Cambridge University Technical Services Ltd. | Methods and means related to cancer stem cells |
| CA2705797A1 (en) * | 2007-11-14 | 2009-05-22 | The Regents Of The University Of California | Sterol-modified amphiphilic lipids |
-
2010
- 2010-06-01 AU AU2010257181A patent/AU2010257181A1/en not_active Abandoned
- 2010-06-01 MX MX2011012823A patent/MX2011012823A/es not_active Application Discontinuation
- 2010-06-01 US US12/802,197 patent/US20110040113A1/en not_active Abandoned
- 2010-06-01 BR BRPI1010175A patent/BRPI1010175A2/pt not_active Application Discontinuation
- 2010-06-01 KR KR1020117031713A patent/KR20120039564A/ko not_active Withdrawn
- 2010-06-01 AP AP2012006053A patent/AP2012006053A0/xx unknown
- 2010-06-01 JP JP2012513928A patent/JP2012528857A/ja active Pending
- 2010-06-01 WO PCT/US2010/001590 patent/WO2010141069A2/en not_active Ceased
- 2010-06-01 CN CN2010800303714A patent/CN102665685A/zh active Pending
- 2010-06-01 EP EP10783699A patent/EP2437756A2/en not_active Withdrawn
- 2010-06-01 CA CA2763819A patent/CA2763819A1/en not_active Abandoned
-
2011
- 2011-12-01 IL IL216719A patent/IL216719A0/en unknown
- 2011-12-02 CL CL2011003049A patent/CL2011003049A1/es unknown
- 2011-12-20 ZA ZA2011/09366A patent/ZA201109366B/en unknown
- 2011-12-30 CO CO11181678A patent/CO6511284A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2012528857A (ja) | 2012-11-15 |
| CA2763819A1 (en) | 2010-12-09 |
| AP2012006053A0 (en) | 2012-02-29 |
| ZA201109366B (en) | 2012-08-29 |
| US20110040113A1 (en) | 2011-02-17 |
| AU2010257181A1 (en) | 2012-01-12 |
| MX2011012823A (es) | 2012-06-25 |
| CN102665685A (zh) | 2012-09-12 |
| CL2011003049A1 (es) | 2012-07-13 |
| EP2437756A2 (en) | 2012-04-11 |
| KR20120039564A (ko) | 2012-04-25 |
| BRPI1010175A2 (pt) | 2016-03-29 |
| IL216719A0 (en) | 2012-02-29 |
| WO2010141069A2 (en) | 2010-12-09 |
| WO2010141069A3 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6511284A2 (es) | Conjugados peg-lipido puros | |
| CY1124769T1 (el) | Βελτιωμενο σκευασμα λιπιδιων | |
| CY1125209T1 (el) | Πεγκυλιωμενα λιποσωματα για χορηγηση rna το οποιο κωδικοποιει ενα ανοσογονο | |
| MX2020011672A (es) | Peptidos novedosos y acidos nucleicos de los mismos contra tumores tal como los de cancer gastrico y gastrointestinal. | |
| CY1110536T1 (el) | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης i ή ii και σχετικο αντικαρκινικο εμβολιο | |
| CU23556A1 (es) | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico | |
| CO6612199A2 (es) | Pèptidos tau antigènicos y usos de los mismos | |
| CY1117237T1 (el) | Συνθεσεις σταθερων τιακουμυκινων | |
| DOP2010000379A (es) | Compuestos de insulina lispro pegilada | |
| CY1119941T1 (el) | Σταθερα και διαλυτα αντισωματα | |
| MX2023006541A (es) | Formulaciones de dosis fija. | |
| CO6361902A2 (es) | Composiciones de organogel y procesos para su producción | |
| AR078247A1 (es) | Vacuna de pcsk9 | |
| MX2011006301A (es) | Produccion de alcoholes de cadena ramificada por medio de microorganismos fotosinteticos. | |
| MX2010001088A (es) | Composicion de peptidos asociados a tumor y vacunas relacionadas contra el cancer. | |
| CL2008002946A1 (es) | Compuestos derivados de quinazolindionas sustituidas, inhibidores pde7 y pde8; composicion farmaceutica que los comprende; procedimiento de preparacion de estos; y usos en el tratamiento y/o prevencion de enfermedades inflamatorias, inmuno inflamatorias, gi, oseas, cancer, entre otras. | |
| AR072205A1 (es) | Metodos para ramificar pha usando termolisis | |
| MX2011009808A (es) | Agentes de elaboracion de imagen optica. | |
| UY31645A1 (es) | Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso. | |
| MX2019000277A (es) | Conjugados polimero-farmaco escindibles. | |
| AR092372A1 (es) | Formulaciones de liposomas, uso y metodo de tratamiento | |
| CU23792A3 (es) | Novedosos anticuerpos antiproliferación | |
| GT201200028A (es) | Derivados de amidas espirocíclicas | |
| BRPI0820258B8 (pt) | composto, composições de vacina, e, uso de um composto | |
| WO2012082483A3 (en) | Multifunctional linkers and methods for the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Application withdrawn |